Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource, 1 online resource.
Sprache
Englisch

Erschienen in
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling ; volume:10 ; number:1 ; day:24 ; month:8 ; year:2023 ; pages:1-18 ; date:12.2023
EJNMMI Physics ; 10, Heft 1 (24.8.2023), 1-18, 12.2023

Urheber
Siebinga, Hinke
Wit-van der Veen, Berlinda J. de
Beijnen, Jos H.
Stokkel, Marcel P. M.
Dorlo, Thomas P. C.
Huitema, Alwin D. R.
Hendrikx, Jeroen J. M. A.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s40658-023-00565-4
URN
urn:nbn:de:101:1-2023110609534927878785
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:45 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Siebinga, Hinke
  • Wit-van der Veen, Berlinda J. de
  • Beijnen, Jos H.
  • Stokkel, Marcel P. M.
  • Dorlo, Thomas P. C.
  • Huitema, Alwin D. R.
  • Hendrikx, Jeroen J. M. A.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Einfluss der Peptid-Radio-Rezeptor-Therapie mittels 90Y- und 177Lu-DOTATATE auf die inflammatorische Atheroskleroseaktivität : Therapiemonitoring mittels serieller 68Ga-DOTATATE Positronenemissionstomographie, Computertomographie

Hochschulschrift

Einfluss der Peptid-Radio-Rezeptor-Therapie mittels 90Y- und 177Lu-DOTATATE auf die inflammatorische Atheroskleroseaktivität : Therapiemonitoring mittels serieller 68Ga-DOTATATE Positronenemissionstomographie, Computertomographie

90Y/177Lu-DOTATATE therapy: survival of the fittest?

90Y/177Lu-DOTATATE therapy: survival of the fittest?

Tissue dose estimation after extravasation of 177Lu-DOTATATE

Tissue dose estimation after extravasation of 177Lu-DOTATATE

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Standardized image quality for 68Ga-DOTA-TATE PET/CT

Standardized image quality for 68Ga-DOTA-TATE PET/CT

p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas

68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy

Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy

A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

Intracranial hemangiopericytoma showing excellent uptake on arterial injection of [68Ga]DOTATATE

Intracranial hemangiopericytoma showing excellent uptake on arterial injection of [68Ga]DOTATATE

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

Verbundene Objekte